<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#Cover" roleURI="http://kairospharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#BalanceSheets" roleURI="http://kairospharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#BalanceSheetsParenthetical" roleURI="http://kairospharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#StatementsOfOperations" roleURI="http://kairospharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#StatementsOfShareholdersEquity" roleURI="http://kairospharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#StatementsOfCashFlows" roleURI="http://kairospharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#BasisOfPresentation" roleURI="http://kairospharma.com/role/BasisOfPresentation" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#VendorAgreements" roleURI="http://kairospharma.com/role/VendorAgreements" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#DeferredOfferingCosts" roleURI="http://kairospharma.com/role/DeferredOfferingCosts" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ShareholdersEquity" roleURI="http://kairospharma.com/role/ShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#CommitmentsAndContingencies" roleURI="http://kairospharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SegmentInformation" roleURI="http://kairospharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SubsequentEvents" roleURI="http://kairospharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#VendorAgreementsTables" roleURI="http://kairospharma.com/role/VendorAgreementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ShareholdersEquityTables" roleURI="http://kairospharma.com/role/ShareholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SegmentInformationTables" roleURI="http://kairospharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#BasisOfPresentationDetailsNarrative" roleURI="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" roleURI="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfVendorAdvancesDetails" roleURI="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfVendorAdvancesDetailsParenthetical" roleURI="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#VendorAgreementsDetailsNarrative" roleURI="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#DeferredOfferingCostsDetailsNarrative" roleURI="http://kairospharma.com/role/DeferredOfferingCostsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfRestrictedCommonStockActivityDetails" roleURI="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfOutstandingAndExercisableWarrantsDetails" roleURI="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ShareholdersEquityDetailsNarrative" roleURI="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#ScheduleOfSegmentExpensesDetails" roleURI="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SegmentInformationDetailsNarrative" roleURI="http://kairospharma.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="kapa-20260331.xsd#SubsequentEventsDetailsNarrative" roleURI="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_KAPAVendorAdvancesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_AmortizationOfVendorAdvances" xlink:label="loc_KAPAAmortizationOfVendorAdvances" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KAPAAmortizationOfVendorAdvances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_FairValueOfVestedRestrictedStockUnits" xlink:label="loc_KAPAFairValueOfVestedRestrictedStockUnits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KAPAFairValueOfVestedRestrictedStockUnits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_IncreaseDecreaseInVendorAdvances" xlink:label="loc_KAPAIncreaseDecreaseInVendorAdvances" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KAPAIncreaseDecreaseInVendorAdvances" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_ProceedsFromAtMarketOffering" xlink:label="loc_KAPAProceedsFromAtMarketOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_KAPAProceedsFromAtMarketOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentation" xlink:title="999012 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreements" xlink:title="999014 - Disclosure - VENDOR AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/DeferredOfferingCosts" xlink:title="999015 - Disclosure - DEFERRED OFFERING COSTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquity" xlink:title="999016 - Disclosure - SHAREHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformation" xlink:title="999018 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEvents" xlink:title="999019 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsTables" xlink:title="999022 - Disclosure - VENDOR AGREEMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityTables" xlink:title="999023 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999025 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999026 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetails" xlink:title="999028 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details)">
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_VendorAdvancesNet" xlink:label="loc_KAPAVendorAdvancesNet" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_VendorAdvancesGross" xlink:label="loc_KAPAVendorAdvancesGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_KAPAVendorAdvancesNet" xlink:to="loc_KAPAVendorAdvancesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="kapa-20260331.xsd#KAPA_VendorAdvancesAccumulatedAmortization" xlink:label="loc_KAPAVendorAdvancesAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_KAPAVendorAdvancesNet" xlink:to="loc_KAPAVendorAdvancesAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfVendorAdvancesDetailsParenthetical" xlink:title="999029 - Disclosure - SCHEDULE OF VENDOR ADVANCES (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/VendorAgreementsDetailsNarrative" xlink:title="999030 - Disclosure - VENDOR AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/DeferredOfferingCostsDetailsNarrative" xlink:title="999031 - Disclosure - DEFERRED OFFERING COSTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfRestrictedCommonStockActivityDetails" xlink:title="999032 - Disclosure - SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999033 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfOutstandingAndExercisableWarrantsDetails" xlink:title="999034 - Disclosure - SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ShareholdersEquityDetailsNarrative" xlink:title="999035 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/ScheduleOfSegmentExpensesDetails" xlink:title="999037 - Disclosure - SCHEDULE OF SEGMENT EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999038 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://kairospharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
